Razvitie BioTechnologii, a member of the Artgen Group, conducted preclinical studies of the effect on the immune system of the new immunomodulator Betusfera when administered intramuscularly and systemically. Drug has proven its ability to enhance immune system activity to fight acute viral infections and increase macrophage activity, which is important for people with reduced immunity. Next stage will be the evaluation of the intranasal form of the drug.